• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » House votes to repeal medical device tax, delay Obamacare

House votes to repeal medical device tax, delay Obamacare

September 29, 2013 By Brad Perriello

The U.S. House of Representatives voted today to repeal the medical device tax and delay the implementation of Obamacare by a year. Both the White House and Sen. Harry Reid (D-Nev.) immediately promised to reject the vote, setting the stage for a government shutdown.

The House voted 248-174 to repeal the tax and 231-192 to delay Obamacare by a year. The measures are pegged to a continuing resolution that would keep the federal government funded until Dec. 15, forestalling the shutdown slated for the Oct. 1 start of the federal fiscal year.

“Tonight the House voted to keep the government open and American medical device innovation alive,” said Congressman Paulsen. “Medical device innovation affects us all, accounting for more than 400,000 U.S. jobs and countless new life-saving and life-improving technologies,” said Rep. Erik Paulsen (R-Minn.), who sponsored the amendment to repeal the device tax, in prepared remarks.

The House has voted more than 40 times to repeal Obamacare and last year approved a measure to repeal the medtech tax, a 2.3% levy on all U.S. sales of prescribed medical devices that’s projected to raise $30 billion over 10 years. It was designed to help pay for Obamacare, in return for an influx of newly insured patients the tax’s architects forecast as a result of the healthcare law.

Earlier this year a symbolic, non-binding repeal vote passed the Senate 79-20. A measure to repeal the tax easily passed in the House last year on a 242-173 vote; a spokesman for Paulsen, that bill’s sponsor, told MassDevice.com today via email that another bid has 263 co-sponsors, including 38 Democrats.

"Since reintroducing his bill to repeal the medical device tax in February, Rep. Paulsen has been pushing leadership hard for a vote," according to the email from Philip Minardi. "This onerous tax on American medical innovation has already cost over 10k US jobs. It’s time for its repeal."

Yesterday, some 941 medical device companies sent a letter to Reid and the other Congressional leaders to "respectfully request that repeal of the medical device excise tax be addressed as a top priority."

"Implementation of what was to be a $20 billion excise tax – and is now estimated to collect over $30 billion in taxes – is adversely impacting patient care and innovation, and will substantially increase the costs of health care. The Senate and House have both passed repeal legislation with strong bipartisan majorities. On behalf of the more than 975 undersigned organizations, associations, companies, patients, providers and venture capital firms representing hundreds of thousands medical technology jobs, we ask that you act to repeal the medical device tax during this session of Congress," according to the letter.

White House press secretary Jay Carney said in a statement that the House vote amounts to "sabotage" of the healthcare law for the sake of ideology.

"Congress has two jobs to do: pass budgets and pay the bills it has racked up. Republicans in Congress had the opportunity to pass a routine, simple continuing resolution that keeps the government running for a few more weeks. But instead, Republicans decided they would rather make an ideological point by demanding the sabotage of the health care law," Carney wrote. "Republicans have tried and failed to defund or delay the health care law more than 40 times, and they know this demand is reckless and irresponsible. The president has shown that he is willing to improve the health care law and meet Republicans more than halfway to deal with our fiscal challenges, but he will not do so under threats of a government shutdown that will hurt our economy. Any member of the Republican Party who votes for this bill is voting for a shutdown. It’s time for the House to listen to the American people and act, as the Senate has, in a reasonable way to pass a bill that keeps the government running and move on."

Reid, who earlier this week called the medical device tax "stupid" (a spokesman later sought to walk that comment back, saying Reid meant that the move to repeal the tax is stupid), said yesterday that the vote on the tax and the Obamacare delay has no chance in the Senate.

"To be absolutely clear, the Senate will reject both the one-year delay of the Affordable Care Act and the repeal of the medical device tax," Reid said. "After weeks of futile political games from Republicans, we are still at square one: Republicans must decide whether to pass the Senate’s clean CR, or force a Republican government shutdown."

The medtech made headlines last week, with prominent legislators from both sides of the aisle joining the push for repeal. Sen. Orrin Hatch (R-Utah), co-author with Sen. Amy Klobuchar (D-Minn.) of a repeal bid, termed the tax a "stupid dumb-ass thing" earlier this week. The measure gained a 5th Democratic supporter when North Carolina’s junior senator, Kay Hagan, signed on Sept. 23.

Hatch’s remarks followed a joint statement from John McCain (R-Ariz.) and Lindsay Graham (R-S.C.) opened up a new front in the war against the tax in a joint statement citing the "egregious" tax’s "destructive" impact on the U.S. medtech industry.

Sen. Max Baucus (D-Mont.) didn’t mince words when asked about some colleagues’ push this week to repeal the medical device tax enacted this year as part of Obamacare, telling the medtech industry that, "A deal’s a deal."

"That industry contributed to a solution; they agreed to the tax, essentially, as did other industries. It’s improper at this point to go back on the deal," Baucus said. "Also, it’d leave a deficit hole. … Who’s going to pay for getting them off the hook?"

Filed Under: News Well Tagged With: U.S. Congress, White House

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS